Topics:

Oncology and Hematology News and Journal Articles

FDA Approves Ramucirumab for Second-Line Treatment of mCRC

The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.

Recent Content

The CONCUR trial found that regorafenib improved overall survival in a large group of Asian patients with treatment-refractory metastatic colorectal cancer.

A new study suggests that a family history of breast cancer does not result in a worse prognosis breast cancer prognosis.

The Federal Trade Commission has charged four US cancer charities with fraud, accusing them of diverting more than $187 million in charitable donations.

Patients with acute myeloid leukemia who had a DNMT3A mutation had poorer disease prognosis, according to an analysis of patients aged 60 years or younger.

A prospective study found that a bronchial airway gene-expression classifier improved the diagnostic performance of bronchoscopy for lung cancer detection.

Autologous stem cell transplant led to significantly longer overall survival than non-transplant strategies in a cohort of elderly patients with multiple myeloma.

Women who were treated for Hodgkin lymphoma during childhood and adolescence had similar rates of post-treatment parenthood as that of the general population.

By clicking Accept, you agree to become a member of the UBM Medica Community.